Human | BIRC7 | 79444 | baculoviral IAP repeat containing 7 | Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. CONCLUSIONS: Our findings suggest that LIVIN may be involved in the progression of superficial bladder cancer and used as a marker of early recurrence; while the expression of SURVIVIN cannot be used to identify patients with high risk of relapse. |
Human | WNT7B | 7477 | wingless-type MMTV integration site family, member 7B | High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer. |
Human | VEGFA | 7422 | vascular endothelial growth factor A | expression levels of VEGF and bFGF were correlated with the biological behavior of superficial transitional cell bladder carcinoma |
Human | TOP2A | 7153 | topoisomerase (DNA) II alpha 170kDa | Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. Biopsies of superficial bladder cancer were analysed to study the relationship between response to epirubicin and the expression of the human topoisomerase II alpha and beta genes. |
Human | TIMP2 | 7077 | TIMP metallopeptidase inhibitor 2 | In addition, Coxs multivariate analysis revealed that elevated MMP-9 and TIMP-2 were strongly associated with a high incidence of intravesical recurrence of superficial bladder cancer. |
Human | TFRC | 7037 | transferrin receptor (p90, CD71) | A group of 65 patients with superficial bladder carcinoma was followed for 2 years and tumour recurrence rate was correlated both with transferrin receptor status of the initial primary tumour and with the results of voided urine cytology. |
Human | TFF1 | 7031 | trefoil factor 1 | Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. |
Human | SLC2A1 | 6513 | solute carrier family 2 (facilitated glucose transporter), member 1 | HIF-1alpha may have a role in recurrence and survival in superficial bladder cancer, while Glut-1 may have a role in survival in invasive bladder cancer |
Human | PAX5 | 5079 | paired box 5 | The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. |
Human | TNFRSF11B | 4982 | tumor necrosis factor receptor superfamily, member 11b | Within the subpopulation of patients with superficial bladder carcinoma, after a follow-up period of 5 years, those who had low serum OPG levels tended to have a longer postoperative tumor-free interval compared with those who had high serum OPG levels. |
Human | NFKB1 | 4790 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | NFKB1 promoter polymorphism is a useful marker for the identification of patients with superficial bladder cancer |
Human | MGAT5 | 4249 | mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase | CONCLUSIONS: Immunohistochemical detection of GnT-V is an independent predictor of superficial bladder cancer recurrence. Carbohydrate structural analysis revealed that superficial bladder cancer is rich in branched N-linked oligosaccharides, for which biosynthesis GnT-V is responsible. We determined whether GnT-V expression is predictive of superficial bladder cancer recurrence. |
Human | IGFBP3 | 3486 | insulin-like growth factor binding protein 3 | We investigated the effect of fenretinide on circulating IGF-I, IGF-II and IGFBP-3 measured at yearly intervals during the 2-year treatment period and one year after treatment discontinuation in a predominantly male population of patients with superficial bladder cancer. |
Human | HIF1A | 3091 | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | HIF-1alpha may have a role in recurrence and survival in superficial bladder cancer, while Glut-1 may have a role in survival in invasive bladder cancer The Kaplan-Meier survival analysis curve shows a significant association of HIF-1alpha expression with recurrence and survival in superficial bladder cancer and shows a significant association of Glut-1 with survival in invasive bladder cancer [chi(2) (4)=10.52; Pr >chi(2) =0.0012]. |
Human | FGFR3 | 2261 | fibroblast growth factor receptor 3 | The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Mutations were detected in 12 of 13 (92.3%) tumor tissues and 11 of 13 (84.6%) urine samples from patients with superficial bladder cancer The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. |
Human | CDKN2B | 1030 | cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. |
Human | CD68 | 968 | CD68 molecule | Immunohistochemical staining using CD68/horseradish peroxidase monoclonal antibody showed more infiltrating cells in invasive than superficial bladder cancers. |
Human | CEACAM1 | 634 | carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell carcinoma in situ (pTis). |
Human | CCND1 | 595 | cyclin D1 | The CCND1 variant A allele may recessively increase the risk of carcinoma in situ incidence in patients with superficial bladder cancer |
Human | AMFR | 267 | autocrine motility factor receptor, E3 ubiquitin protein ligase | Positive expression of E-cadherin and negative expression of gp78 were found to be associated with a low risk of clinical progression in the superficial bladder carcinoma patient group. |